adherence difficulties associated with currently available medications for treating drug-resistant TB. Multiple delamanid trials have evaluated safety, tolerability, and early bactericidal activity (1, 2) . Delamanid use, in combination with World Health Organization (WHO)-recommended drugs for drugresistant TB, has shown improvement in treatment outcomes (3) (4) (5) and effectiveness against XDR TB, for which treatment options are limited (6) . A U.S. physician, in conjunction with a TB COE and CDC's Division of Tuberculosis Elimination, collaborated to acquire delamanid for this patient with XDR TB through a compassionate use program.
Per pharmaceutical manufacturer instructions, the proposed regimen and monitoring protocols were reviewed and approved by the European Respiratory Society/WHO Consilium, after which the treating physician was instructed to file an emergency investigational new drug application for single-patient expanded-access with FDA. Within 1 day of submission of the forms, FDA approved the emergency investigational new drug application for delamanid. The treating physician completed a company-sponsored 90-minute pharmacovigilance training webinar via teleconference. After requirements were fulfilled, medications were shipped. A 6-month supply of delamanid arrived within 5 days of application approval, and the patient was started on delamanid in late August. The patient's initial symptoms, which included fatigue, anorexia, and cough, improved within the first month of treatment. His sputum smear converted to negative on August 22 and culture converted to negative October 31. The patient is continuing on a 24-month treatment plan at this time with continued clinical improvement and no reported adverse effects.
The process from application filing to delamanid initiation took 4 weeks. The pharmaceutical company provided clear instructions, contact information for concerns faced by the physician during treatment, and assistance completing FDA single-patient expanded-access forms. Physicians and state or local TB providers considering use of delamanid for their TB patients can seek guidance from CDC's Division of Tuberculosis Elimination or their regional CDC-funded TB COE. † Prompt access to this new anti-TB drug increased therapeutic options for this patient with XDR disease. † CDC's Division of Tuberculosis Elimination can be reached at 404-639-8120.
Local CDC-funded TB COEs can be found at https://www.cdc.gov/tb/ education/tb_coe/default.htm.
